Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors

Inclusion Criteria:

• Able to provide written informed consent

• Advanced, progressing solid tumor that has no cure

  • In Stage 1, any advanced solid malignancy
  • In Stage 2, advanced breast cancer, melanoma, or non-small cell lung cancer (NSCLC)
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2
• Recovered from radiation therapy that may have been given in the last 21 days
• Recovered from surgery

Exclusion Criteria:

• Prior exposure to SNS-032 (previously known as BMS-387032)
• Pregnant or breastfeeding
• Women or male partners of women who are able to have children but are unwilling to use an approved, effective means of birth control
• Took part in another clinical trial during the last 21 days
• Abnormal lab values for serum potassium, hemoglobin, neutrophils, platelets, creatinine, AST, ALT, or total bilirubin
• Brain metastases, if patient is not neurologically stable or has needed corticosteroids or anticonvulsants at anytime within the 28 day period before enrollment.
• Other active malignancies
• Prior pelvic radiation therapy to ≥ 25% of bone marrow reserve
• Any other condition that would keep the patient from safely taking part in the clinical trial

Please note: There are additional inclusion/exclusion criteria for this study. Please contact the study center for additional information and to determine if all study criteria are met.